Aprea Therapeutics, Inc.
No enriched coverage for $APRE in the last 7 days.
No SEC Form 4 filings for $APRE in the last 30 days.
Aprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.
Aprea Therapeutics (NASDAQ: APRE) has registered 74,349,426 shares of Common Stock for resale by selling stockholders. This registration covers shares issuable upon the exercise of both pre-funded warrants (37,174,713 shares) and common warrants (37,174,713 shares) that were issued in a private placement on March 31, 2026. Aprea Therapeutics will not receive proceeds from the resales themselves but will receive cash if the outstanding warrants are exercised, with proceeds intended for clinical trials, working capital, and general corporate purposes.
Aprea Therapeutics announced that its abstract detailing early results from the first-in-human Phase 1 ACESOT-1051 study of the WEE1 inhibitor APR-1051 for advanced solid tumors has been accepted for presentation at the ASCO 2026 Annual Meeting. The presentation will be a poster session on May 30, 2026, featuring initial safety and activity findings. This marks a significant clinical milestone, with investors closely watching for efficacy, safety, and biomarker data.
